Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

• the present invention relates to phthalazinone derivatives, and their use as pharmaceuticals.
• the present invention relates to the use of these compounds to inhibit the activity of the enzyme poly (ADP-ribose)polymerase-i , also known as poly(ADP- ribose)synthase and poly ADP-ribosyltransferase, and commonly referred to as PARP-1.
• poly (ADP-ribose)polymerase-i also known as poly(ADP- ribose)synthase and poly ADP-ribosyltransferase, and commonly referred to as PARP-1.
• the mammalian enzyme PARP-1 (a 113-kDa multidomain protein) has been implicated in the signalling of DNA damage through its ability to recognize and rapidly bind to DNA single or double strand breaks (D'Amours, et al., Biochem. J., 342, 249-268 (1999)).
• the family of Poly (ADP-ribose) polymerases now includes around 18 proteins, that all display a certain level homology in their catalytic doimain but differ in their cellular functions (Ame et a/., Bioessays., 26(8), 882-893 (2004)).
• PARP-1 the founding member
• PARP-2 the sole enzymes whose catalytic activity are stimulated by the occurrence of DNA strand breaks, making them unique in the family.
• PARP-1 participates in a variety of DNA-related functions including gene amplification, cell division, differentiation, apoptosis, DNA base excision repair as well as effects on telomere length and chromosome stability (d'Adda di Fagagna, et al., Nature Gen., 23(1), 76-80 (1999)).
• the DNA-bound, activated PARP-1 utilizes NAD + to synthesize poly (ADP-ribose) on a variety of nuclear target proteins, including topoisomerases, histones and PARP itself (Rhun, et al., Biochem. Biophys. Res. Commun., 245, 1-10 (1998))
• Poly (ADP-ribosyl)ation has also been associated with malignant transformation.
• PARP-1 activity is higher in the isolated nuclei of SV40-transformed fibroblasts, while both leukemic cells and colon cancer cells show higher enzyme activity than the equivalent normal leukocytes and colon mucosa (Miwa, et al., Arch. Biochem. Biophys., 181, 313-321 (1977); Burzio, et al., Proc. Soc. Exp. Bioi. Med., 149, 933-938 (1975); and Hirai, et al., Cancer Res., 43, 3441-3446 (1983)).
• a number of low-molecular-weight inhibitors of PARP-1 have been used to elucidate the functional role of poly (ADP-ribosyl)ation in DNA repair.
• the inhibition of PARP leads to a marked increase in DNA-strand breakage and cell killing (Durkacz, et al., Nature, 283, 593-596 (1980); Berger, N.A., Radiation Research, 101, 4-14 (1985)).
• PARP-1 knockout (PARP -/-) animals exhibit genomic instability in response to alkylating agents and ⁇ -irradiation (Wang, et al., Genes Dev., 9, 509-520 (1995); Menissier de Murcia, ef al., Proc. Natl. Acad. ScL USA, 94, 7303-7307 (1997)). More recent data indicates that PARP-1 and PARP-2 possess both overlapping and non-redundant functions in the maintenance of genomic stability, making them both interesting targets (Menissier de Murcia, et al., EMBO. J., 22(9), 2255-2263 (2003)).
• a role for PARP-1 has also been demonstrated in certain vascular diseases, septic shock, ischaemic injury and neurotoxicity (Cantoni, et al., Biochim. Biophys. Acta, 1014, 1-7 (1989); Szabo, et al., J. CHn. Invest, 100, 723-735 (1997)).
• Oxygen radical DNA damage that leads to strand breaks in DNA, which are subsequently recognised by PARP-1 is a major contributing factor to such disease states as shown by PARP-1 inhibitor studies (Cosi, ef al., J. Neurosci. Res., 39, 38-46 (1994); Said, et al., Proc. Natl. Acad.
• PARP-1 inhibition has been speculated to delay the onset of aging characteristics in human fibroblasts (Rattan and Clark, Biochem. Biophys. Res. Comm., 201(2), 665-672 (1994)). This may be related to the role that PARP plays in controlling telomere function (d'Adda di Fagagna, et al., Nature Gen., 23(1), 76-80 (1999)).
• PARP-1 inhibitors are also thought to be relevant to the treatment of inflammatory bowel disease (Szabo C, Role of Poly(ADP-Ribose) Polymerase Activation in the Pathogenesis of Shock and Inflammation, In PARP as a Therapeutic Target; Ed J. Zhang, 2002 by CRC Press; 169-204), ulcerative colitis (Zingarelli, B, et al., Immunology, 113(4), 509-517 (2004)) and Crohn's disease (Jijon, H. B., et al., Am. J. Physiol. Gastrointest. Liver Physiol., 279, G641-G651 (2000).
• R 0 is represented by -L-R L .
• R represent one or more optional substituents.
• the present inventors have now discovered that compounds where R is of a certain nature and the phenyl group is replaced exhibit surprising levels of inhibition of the activity of PARP, and/or of potentiation of tumour cells to radiotherapy and various chemotherapies.
• the first aspect of the present invention provides a compound of the formula (I):
• a and B together represent an optionally substituted, fused aromatic ring;
• R x is selected from the group consisting of H, optionally substituted Ci -2 o alkyl, 0 5 . 20 aryl, C 3-2O heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups;
• R ⁇ is selected from H, hydroxy, amino; or R x and R ⁇ may together form a spiro-C 3 .
• R C1 and R 02 are independently selected from the group consisting of hydrogen and C-M alkyl, or when X is CR X R Y , R c1 , R C2 , R x and R ⁇ , together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring;
• R 1 is selected from H and halo; and
• Het is selected from: CO
• Y 1 is selected from CH and N
• Y z is selected from CH and N
• Y 3 is selected from CH, CF and N, where only one or two of Y 1 , Y 2 and Y 3 can be N; and ( ⁇ )
• a second aspect of the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of the first aspect and a pharmaceutically acceptable carrier or diluent.
• a third aspect of the present invention provides the use of a compound of the first aspect in a method of treatment of the human or animal body.
• a fourth aspect of the present invention provides the use of a compound as defined in the first aspect of the invention in the preparation of a medicament for: (a) preventing poly(ADP-ribose) chain formation by inhibiting the activity of cellular PARP (PARP-1 and/or PARP-2);
• compounds as defined in the first aspect of the invention can be used in anti ⁇ cancer combination therapies (or as adjuncts) along with alkylating agents, such as methyl methanesulfonate (MMS) , temozolomide and dacarbazine (DTIC) 1 also with topoisomerase- 1 inhibitors like Topotecan, Irinotecan, Rubitecan, Exatecan, Lurtotecan, Gimetecan, Diflomotecan (homocamptothecins); as well as 7-substituted non-silatecans; the 7-silyl camptothecins, BNP 1350; and non-camptothecin topoisomerase-l inhibitors such as indolocarbazoles also dual topoisomerase-l and Il inhibitors like the benzophenazines, XR 11576/MLN 576 and benzopyridoindoles.
• alkylating agents such as methyl methanesulfonate (
• compositions for the treatment of disease ameliorated by the inhibition of PARP, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound as defined in the first aspect, preferably in the form of a pharmaceutical composition and the treatment of cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound as defined in the first aspect in combination, preferably in the form of a pharmaceutical composition, simultaneously or sequentially with radiotherapy (ionizing radiation) or chemotherapeutic agents.
• radiotherapy ionizing radiation
• chemotherapeutic agents ionizing radiation
• the compounds may be used in the preparation of a medicament for the treatment of cancer which is deficient in Homologous Recombination (HR) dependent DNA double strand break (DSB) repair activity, or in the treatment of a patient with a cancer which is deficient in HR dependent DNA DSB repair activity, comprising administering to said patient a therapeutically-effective amount of the compound.
• HR Homologous Recombination
• DSB DNA double strand break
• the HR dependent DNA DSB repair pathway repairs double-strand breaks (DSBs) in DNA via homologous mechanisms to reform a continuous DNA helix (K.K. Khanna and SP. Jackson, Nat. Genet. 27(3): 247-254 (2001)).
• the components of the HR dependent DNA DSB repair pathway include, but are not limited to, ATM (NMJ3OOO51), RAD51
• NM_002875 RAD51L1 (NM_002877), RAD51C (NM_002876), RAD51L3 (NM_002878), DMC1 (NM_007068), XRCC2 (NM_005431), XRCC3 (NM_005432), RAD52 (NM_002879), RAD54L (NM_003579), RAD54B (NM_012415), BRCA1 (NM_007295), BRCA2 (NM_000059), RAD50 (NM_005732), MRE11A (NM_005590) and NBS1 (NM_002485).
• HR dependent DNA DSB repair pathway Other proteins involved in the HR dependent DNA DSB repair pathway include regulatory factors such as EMSY (Hughes-Davies, et al., Cell, 115, pp523-535). HR components are also described in Wood, et al., Science, 291, 1284-1289 (2001).
• a cancer which is deficient in HR dependent DNA DSB repair may comprise or consist of one or more cancer cells which have a reduced or abrogated ability to repair DNA DSBs through that pathway, relative to normal cells i.e. the activity of the HR dependent DNA DSB repair pathway may be reduced or abolished in the one or more cancer cells.
• the activity of one or more components of the HR dependent DNA DSB repair pathway may be abolished in the one or more cancer cells of an individual having a cancer which is deficient in HR dependent DNA DSB repair.
• Components of the HR dependent DNA DSB repair pathway are well characterised in the art (see for example, Wood, et a/., Science, 291, 1284-1289 (2001)) and include the components listed above.
• the cancer cells may have a BRCA1 and/or a BRCA2 deficient phenotype i.e. BRCA1 and/or BRCA2 activity is reduced or abolished in the cancer cells.
• Cancer cells with this phenotype may be deficient in BRCA1 and/or BRCA2, i.e.
• BRCA1 and/or BRCA2 may be reduced or abolished in the cancer cells, for example by means of mutation or polymorphism in the encoding nucleic acid, or by means of amplification, mutation or polymorphism in a gene encoding a regulatory factor, for example the EMSY gene which encodes a BRCA2 regulatory factor (Hughes- Davies, et a/., Ce//, 115, 523-535) or by an epigenetic mechanism such as gene promoter methylation.
• a regulatory factor for example the EMSY gene which encodes a BRCA2 regulatory factor (Hughes- Davies, et a/., Ce//, 115, 523-535) or by an epigenetic mechanism such as gene promoter methylation.
• BRCA1 and BRCA2 are known tumour suppressors whose wild-type alleles are frequently lost in tumours of heterozygous carriers (Jasin M., Oncogene, 21(58), 8981-93 (2002); Tutt, etal., Trends MoI Med., 8(12), 571-6, (2002)).
• the association of BRCA1 and/or BRCA2 mutations with breast cancer is well-characterised in the art (Radice, P.J., Exp Clin Cancer Res., 21(3 Suppl), 9-12 (2002)).
• Amplification of the EMSY gene, which encodes a BRCA2 binding factor, is also known to be associated with breast and ovarian cancer.
• Carriers of mutations in BRCA1 and/or BRCA2 are also at elevated risk of cancer of the ovary, prostate and pancreas.
• the individual is heterozygous for one or more variations, such as mutations and polymorphisms, in BRCA1 and/or BRCA2 or a regulator thereof.
• variations such as mutations and polymorphisms
• the detection of variation in BRCA1 and BRCA2 is well-known in the art and is described, for example in EP 699 754, EP 705 903, Neuhausen, S.L. and Ostrander, E.A., Genet. Test, 1, 75-83 (1992); Janatova M., et al., Neoplasma, 50(4), 246-50 (2003).
• Determination of amplification of the BRCA2 binding factor EMSY is described in Hughes-Davies, et al., Cell, 115, 523-535).
• Mutations and polymorphisms associated with cancer may be detected at the nucleic acid level by detecting the presence of a variant nucleic acid sequence or at the protein level by detecting the presence of a variant (i.e. a mutant or allelic variant) polypeptide.
• aromatic ring is used herein in the conventional sense to refer to a cyclic aromatic structure, that is, a cyclic structure having delocalised ⁇ -electron orbitals.
• the aromatic ring fused to the main core i.e. that formed by -A-B-, may bear further fused aromatic rings (resulting in, e.g. naphthyl or anthracenyl groups).
• the aromatic ring(s) may comprise solely carbon atoms, or may comprise carbon atoms and one or more heteroatoms, including but not limited to, nitrogen, oxygen, and sulfur atoms.
• the aromatic ring(s) preferably have five or six ring atoms.
• the aromatic ring(s) may optionally be substituted. If a substituent itself comprises an aryl group, this aryl group is not considered to be a part of the aryl group to which it is attached.
• the group biphenyl is considered herein to be a phenyl group (an aryl group comprising a single aromatic ring) substituted with a phenyl group.
• the group benzylphenyl is considered to be a phenyl group (an aryl group comprising a single aromatic ring) substituted with a benzyl group.
• the aromatic group comprises a single aromatic ring, which has five or six ring atoms, which ring atoms are selected from carbon, nitrogen, oxygen, and sulfur, and which ring is optionally substituted.
• these groups include, but are not limited to, benzene, pyrazine, pyrrole, thiazole, isoxazole, and oxazole.
• 2-Pyrone can also be considered to be an aromatic ring, but is less preferred.
• the aromatic ring has six atoms, then preferably at least four, or even five or all, of the ring atoms are carbon.
• the other ring atoms are selected from nitrogen, oxygen and sulphur, with nitrogen and oxygen being preferred.
• Suitable groups include a ring with: no hetero atoms (benzene); one nitrogen ring atom (pyridine); two nitrogen ring atoms (pyrazine, pyrimidine and pyridazine); one oxygen ring atom (pyrone); and one oxygen and one nitrogen ring atom (oxazine).
• Suitable rings include a ring with: one nitrogen ring atom (pyrrole); two nitrogen ring atoms (imidazole, pyrazole); one oxygen ring atom (furan); one sulphur ring atom (thiophene); one nitrogen and one sulphur ring atom (isothiazole, thiazole); and one nitrogen and one oxygen ring atom (isoxazole or oxazole).
• the aromatic ring may bear one or more substituent groups at any available ring position. These substituents are selected from halo, nitro, hydroxy, ether, thiol, thioether, amino, Ci -7 alky!, C 3-2O heterocyclyl and C 5 . 2 o aryl.
• the aromatic ring may also bear one or more substituent groups which together form a ring. In particular these may be of formula -(CH 2 ) m - or -0-(CH 2 ) P -O-, where m is 2, 3, 4 or 5 and p is 1 , 2 or 3.
• Alkyl refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated).
• alkyl includes the sub-classes alkenyl, alkynyl, cycloalkyl, cycloalkyenyl, cylcoalkynyl, etc., discussed below.
• the prefixes denote the number of carbon atoms, or range of number of carbon atoms.
• the term "C 1 - 4 alkyl”, as used herein, pertains to an alkyl group having from 1 to 4 carbon atoms.
• groups of alkyl groups include C 1-4 alkyl ("lower alkyl"), C 1-7 alkyl, and C 1-2O alkyl.
• the first prefix may vary according to other limitations; for example, for unsaturated alkyl groups, the first prefix must be at least 2; for cyclic alkyl groups, the first prefix must be at least 3; etc.
• Examples of (unsubstituted) saturated alkyl groups include, but are not limited to, methyl (C 1 ), ethyl (C 2 ), propyl (C 3 ), butyl (C 4 ), pentyl (C 5 ), hexyl (C 6 ), heptyl (C 7 ), octyl (C 8 ), nonyl (C 9 ), decyl (Ci 0 ), undecyl (C 11 ), dodecyl (Ci 2 ), tridecyl (C 13 ), tetradecyl (C 14 ), pentadecyl (C 15 ), and eicodecyl (C 20 ).
• Examples of (unsubstituted) saturated linear alkyl groups include, but are not limited to, methyl (C-i), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (amyl) (C 5 ), n-hexyl (C 6 ), and n- heptyl (C 7 ).
• Examples of (unsubstituted) saturated branched alkyl groups include, but are not limited to, iso-propyl (C 3 ), iso-butyl (C 4 ), sec-butyl (C 4 ), tert-butyl (C 4 ), iso-pentyl (C 5 ), and neo-pentyl (C 5 ).
• Alkenyl refers to an alkyl group having one or more carbon-carbon double bonds. Examples of alkenyl groups include C 2-4 alkenyl, C 2-7 alkenyl, C 2-20 alkenyl.
• Alkynyl refers to an alkyl group having one or more carbon-carbon triple bonds. Examples of alkynyl groups include C 2-4 alkynyl, C 2-7 alkynyl, C 2-20 alkynyl.
• Examples of (unsubstituted) unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C ⁇ CH) and 2-propynyl (propargyl, -CH 2 -C ⁇ CH).
• Cycloalkyl refers to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound, which carbocyclic ring may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated), which moiety has from 3 to 20 carbon atoms (unless otherwise specified), including from 3 to 20 ring atoms.
• cycloalkyl includes the sub-classes cycloalkenyl and cycloalkynyl.
• each ring has from 3 to 7 ring atoms.
• groups of cycloalkyl groups include C 3-2O cycloalkyl, C 3-15 cycloalkyl, C 3-10 cycloalkyl, C 3-7 cycloalkyl.
• cycloalkyl groups include, but are not limited to, those derived from: saturated monocyclic hydrocarbon compounds: cyclopropane (C 3 ), cyclobutane (C 4 ), cyclopentane (C 5 ), cyclohexane (C 6 ), cycloheptane (C 7 ), methylcyclopropane (C 4 ), dimethylcyclopropane (C 5 ), methylcyclobutane (C 5 ), dimethylcyclobutane (C 6 ), methylcyclopentane (C 6 ), dimethylcyclopentane (C 7 ), methylcyclohexane (C 7 ), dimethylcyclohexane (C 8 ), menthane (C 10 ); unsaturated monocyclic hydrocarbon compounds: cyclopropene (C 3 ), cyclobutene (C 4 ), cyclopentene (C 5 ), cyclohexene (C 6 ), methylcyclopropene
• Heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms.
• each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.
• the prefixes e.g. C 3-20 , C 3-7 , C 5 . 6 , etc.
• the term "C 5 . 6 heterocyclyl”, as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.
• groups of heterocyclyl groups include C 3-20 heterocyclyl, C 5-20 heterocyclyl, C 3- I 5 heterocyclyl, C 5-15 heterocyclyl, C 3-12 heterocyclyl, C 5-12 heterocyclyl, C 3-10 heterocyclyl, C 5-10 heterocyclyl, C 3-7 heterocyclyl, C 5-7 heterocyclyl, and C 5-6 heterocyclyl.
• monocyclic heterocyclyl groups include, but are not limited to, those derived from:
• O 1 oxirane (C 3 ), oxetane (C 4 ), oxolane (tetrahydrofuran) (C 5 ), oxole (dihydrofuran) (C 5 ), oxane (tetrahydropyran) (C 6 ), dihydropyran (C 6 ), pyran (C 6 ), oxepin (C 7 );
• N 2 imidazolidine (C 5 ), pyrazolidine (diazolidine) (C 5 ), imidazoline (C 5 ), pyrazoline (dihydropyrazole) (C 5 ), piperazine (C 6 );
• N 1 O 1 tetrahydrooxazole (C 5 ), dihydrooxazole (C 5 ), tetrahydroisoxazole (C 5 ), dihydroisoxazole (C 5 ), morpholine (C 6 ), tetrahydrooxazine (C 6 ), dihydrooxazine (C 6 ), oxazine (C 6 );
• NiS 1 thiazoline (C 5 ), thiazolidine (C 5 ), thiomorpholine (C 6 );
• O 1 S 1 oxathiole (C 5 ) and oxathiane (thioxane) (C 6 ); and,
• N 1 O 1 S 1 oxathiazine (C 6 ).
• substituted (non-aromatic) monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C 5 ), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C 6 ), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.
• furanoses C 5
• arabinofuranose such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse
• pyranoses C 6
• allopyranose altropyranose
• glucopyranose glucopyranose
• mannopyranose gulopyranose
• idopyranose galactopyr
• Spiro-C 3-7 cycloalkyl or heterocyclyl refers to a C 3-7 cycloalkyl or C 3-7 heterocyclyl ring joined to another ring by a single atom common to both rings.
• C 5-20 aryl refers to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of a C 5-20 aromatic compound, said compound having one ring, or two or more rings (e.g., fused), and having from 5 to 20 ring atoms, and wherein at least one of said ring(s) is an aromatic ring.
• each ring has from 5 to 7 ring atoms.
• the ring atoms may be all carbon atoms, as in "carboaryl groups” in which case the group may conveniently be referred to as a "C 5 . 20 carboaryl” group.
• C 5-20 aryl groups which do not have ring heteroatoms include, but are not limited to, those derived from benzene (i.e. phenyl) (C 6 ), naphthalene (C 10 ), anthracene (Ci 4 ), phenanthrene (C 14 ), and pyrene (C 16 ).
• the ring atoms may include one or more heteroatoms, including but not limited to oxygen, nitrogen, and sulfur, as in “heteroaryl groups".
• the group may conveniently be referred to as a "C 5-20 heteroaryl” group, wherein “C 5-20 " denotes ring atoms, whether carbon atoms or heteroatoms.
• each ring has from 5 to 7 ring atoms, of which from 0 to 4 are ring heteroatoms.
• C 5-20 heteroaryl groups include, but are not limited to, C 5 heteroaryl groups derived from furan (oxole), thiophene (thiole), pyrrole (azole), imidazole (1 ,3-diazole), pyrazole (1 ,2-diazole), triazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, tetrazole and oxatriazole; and C 6 heteroaryl groups derived from isoxazine, pyridine (azine), pyridazine (1 ,2-diazine), pyrimidine (1 ,3-diazine; e.g., cytosine, thymine, uracil), pyrazine (1 ,4-diazine) and triazine.
• C 5 heteroaryl groups derived from furan (oxole), thiophene (thiole
• the heteroaryl group may be bonded via a carbon or hetero ring atom.
• C 5-2O heteroaryl groups which comprise fused rings include, but are not limited to, C 9 heteroaryl groups derived from benzofuran, isobenzofuran, benzothiophene, indole, isoindole; Ci 0 heteroaryl groups derived from quinoline, isoquinoline, benzodiazine, pyridopyridine; C 14 heteroaryl groups derived from acridine and xanthene.
• Halo -F, -Cl, -Br, and -I.
• Ether -OR, wherein R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a Ci -7 alkoxy group), a C 3-2O heterocyclyl group (also referred to as a C 3-2O heterocyclyloxy group), or a C 5-20 aryl group (also referred to as a C 5-20 aryloxy group), preferably a Ci -7 alkyl group.
• R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a Ci -7 alkoxy group), a C 3-2O heterocyclyl group (also referred to as a C 3-2O heterocyclyloxy group), or a C 5-20 aryl group (also referred to as a C 5-20 aryloxy group), preferably a Ci -7 alkyl group.
• R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a Ci -7 al
• R is an acyl substituent, for example, H, a C 1-7 alkyl group (also referred to as C 1-7 alkylacyl or C 1-7 alkanoyl), a C 3-20 heterocyclyl group (also referred to as C 3-20 heterocyclylacyl), or a C 5-2O aryl group (also referred to as C 5-20 arylacyl), preferably a C 1-7 alkyl group.
• R is an acyl substituent, for example, H, a C 1-7 alkyl group (also referred to as C 1-7 alkylacyl or C 1-7 alkanoyl), a C 3-20 heterocyclyl group (also referred to as C 3-20 heterocyclylacyl), or a C 5-2O aryl group (also referred to as C 5-20 arylacyl), preferably a C 1-7 alkyl group.
• Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): -C( O)NR 1 R 2 , wherein R 1 and R 2 are independently amino substituents, as defined for amino groups.
• R 1 and R 2 are independently amino substituents, for example, hydrogen, a C 1 - 7 alkyl group (also referred to as Ci -7 alkylamino or di-Ci -7 alkylamino), a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably H or a Ci -7 alkyl group, or, in the case of a "cyclic" amino group, R 1 and R 2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms.
• R 1 and R 2 are independently amino substituents, for example, hydrogen, a C 1 - 7 alkyl group (also referred to as Ci -7 alkylamino or di-Ci -7 alkylamino), a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably H or a Ci -7 alkyl group, or, in the case of a "cyclic" amino group, R
• amino groups include, but are not limited to, -NH 2 , -NHCH 3 , -NHCH(CH 3 ) 2 , -N(CH 3 J 2 , -N(CH 2 CH 3 ) 2l and -NHPh.
• cyclic amino groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidino, piperazinyl, perhydrodiazepinyl, morpholino, and thiomorpholino.
• the cyclic amino groups may be substituted on their ring by any of the substituents defined here, for example carboxy, carboxylate and amido.
• R 1 is an amide substituent, for example, hydrogen, a Ci -7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably H or a C 1 . 7 alkyl group, most preferably H
• R 2 is an acyl substituent, for example, a Ci -7 alkyl group, a C 3-20 heterocyclyl group,
• R 1 and R 2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:
• R 2 and R 3 are independently amino substituents, as defined for amino groups, and R1 is a ureido substituent, for example, hydrogen, a Ci -7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-2O aryl group, preferably hydrogen or a Ci -7 alkyl group.
• ureido groups include, but are not limited to, -NHCONH 2 , -NHCONHMe, -NHCONHEt, -NHCONMe 2 , -NHCONEt 2 , -NMeCONH 2 , -NMeCONHMe, -NMeCONHEt, - NMeCONMe 2 , -NMeCONEt 2 and -NHCONHPh.
• Acyloxy (reverse ester): -OC( O)R, wherein R is an acyloxy substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a C 1-7 alkyl group.
• C 1-7 alkylthio groups include, but are not limited to, -SCH 3 and -SCH 2 CH 3 .
• R is a sulfone substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a Ci -7 alkyl group.
• Thioamido (thiocarbamyl): -C( S)NR 1 R 2 , wherein R 1 and R 2 are independently amino substituents, as defined for amino groups.
• R 1 is an amino substituent, as defined for amino groups
• R is a sulfonamino substituent, for example, a Ci -7 alkyl group, a C 3-20 heterocyclyl group, or a C 5 - 20 aryl group, preferably a C-i -7 alkyl group.
• the fused aromatic ring(s) represented by -A-B- preferably consist of solely carbon ring atoms, and thus may be benzene, naphthalene, and is more preferably benzene. As described above, these rings may be substituted, but in some embodiments are preferably unsubstituted.
• fused aromatic ring represented by -A-B- bears a substituent group, it is preferably attached to the atom which itself is attached to the central ring ⁇ - to the carbon atom in the central ring.
• the fused aromatic ring is a benzene ring, the preferred place of substitution is shown in the formula below by *:
• the substituent is preferably an alkoxy, amino, halo (e.g. fluoro) or hydroxy group, and more preferably a C 1-7 alkoxy group (e.g. -OMe).
• the substituent is a halo, it may be at the 8-position of the phthalazinone moiety.
• Het is selected from pyridylene, fluro-pyrdiylene, furanylene and thiophenylene.
• Het is selected from:
• Het is selected from:
• R C1 and R C2 are independently selected from hydrogen and Ci -4 alkyl, and more preferably H and methyl. It is more preferred that at least one of R C1 and R C2 are hydrogen, with the most preferred option being that both are hydrogen.
• R x is preferably selected from the group consisting of: H; optionally substituted C 1-2O alkyl (for example, optionally substituted C 5 . 2 o arylmethyl); optionally substituted C 5-20 aryl; optionally substituted ester groups, wherein the ester substituent is preferably Ci -20 alkyl; optionally substituted acyl groups; optionally substituted amido groups; optionally substituted thioamido groups; and optionally substituted sulfonyl groups.
• R x is more preferably selected from the group consisting of: H; optionally substituted C 1-20 alkyl (more preferably optionally substituted C 1-7 alkyl, e.g. methyl); and optionally substituted ester groups, wherein the ester substituent is preferably C- ⁇ -2 o alkyl (more preferably optionally substituted C 1-7 alkyl, e.g. f-butyl).
• X may be NR X or CR X CR Y .
• R x is preferably selected from the group consisting of: H; optionally substituted C 1-20 alkyl (for example, optionally substituted C 5-20 arylmethyl); optionally substituted C 5-20 aryl; optionally substituted acyl; optionally substituted sulfonyl; optionally substituted amido; and optionally substituted thioamido groups.
• Het is pyridylene.
• R x is more preferably selected from the group consisting of: optionally substituted acyl; optionally substituted sulfonyl; and optionally substituted amido.
• R x is more preferably selected from the group consisting of: optionally substituted Ci -20 alkyl (for example, optionally substituted C 5-20 arylmethyl); optionally substituted C 5-20 aryl; optionally substituted acyl; optionally substituted sulfonyl; and optionally substituted amido.
• R ⁇ is preferably H.
• R x is preferably selected from the group consisting of: H; optionally substituted C 1-20 alkyl (for example, optionally substituted C 5-20 arylmethyl); optionally substituted C 5-20 aryl; optionally substituted C 3-20 heterocyclyl; optionally substituted acyl, wherein the acyl substituent is preferably selected from C 5-20 aryl and C 3-20 heterocylyl (e.g.
• piperazinyl optionally substituted amino, wherein the amino groups are preferably selected from H and C 1-20 alkyl or together with the nitrogen atom, form a C 5-2 O heterocyclic group; optionally substituted amido, wherein the amino groups are preferably selected from H and Ci -2 o alkyl or together with the nitrogen atom, form a C 5-2O heterocyclic group; and optionally substituted ester groups, wherein the ester substituent is preferably selected from C 1-20 alkyl groups.
• R x is more preferably selected from optionally substituted amino, wherein the amino groups are preferably selected from H and Ci -20 alkyl or together with the nitrogen atom, form a C 5 . 20 heterocyclic group, e.g. morpholino.
• Particularly preferred compounds include: 2, 3, 5, 6, 9, 10, 12, 13, 56, 57, 58, 62, 65, 66, 67, 74 and 75.
• a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO " ), a salt or solvate thereof, as well as conventional protected forms.
• a reference to an amino group includes the protonated form (-N + HR 1 R 2 ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group.
• a reference to a hydroxy! group also includes the anionic form (-O " ), a salt or solvate thereof, as well as conventional protected forms of a hydroxyl group.
• Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasterioisomeric, epimeric, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and frans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and /-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; ⁇ - and ⁇ - forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers” (or "isomeric forms").
• the compound may exist in a number of different polymorphic forms.
• isomers are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
• a reference to a methoxy group, -OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH 2 OH.
• a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta- chlorophenyl.
• Ci -7 alkyl includes n-propyl and /so-propyl; butyl includes n-, iso-, sec-, and ferf-butyl; methoxyphenyl includes ortho-, meta-, and para- methoxyphenyl).
• keto-, enol-, and enolate-forms as in, for example, the following tautomeric pairs: keto/enol, imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N- nitroso/hyroxyazo, and nitro/aci-nitro.
• H may be in any isotopic form, including 1 H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
• a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner. Unless otherwise specified, a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below, as well as its different polymorphic forms.
• a corresponding salt of the active compound for example, a pharmaceutically-acceptable salt.
• a pharmaceutically-acceptable salt examples are discussed in Berge, et al., "Pharmaceutically Acceptable Salts", J. Pharm. ScL, 66, 1-19 (1977).
• the compound is anionic, or has a functional group which may be anionic
• a salt may be formed with a suitable cation.
• suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
• suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NHaRa + , NHR 3 + , NR 4 + ).
• Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
• An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
• a salt may be formed with a suitable anion.
• suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
• Suitable organic anions include, but are not limited to, those derived from the following organic acids: acetic, propionic, succinic, gycolic, stearic, palmitic, lactic, malic, pamoic, tartaric, citric, gluconic, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, aspartic, benzoic, cinnamic, pyruvic, salicyclic, sulfanilic, 2-acetyoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanesulfonic, ethane disulfonic, oxalic, isethionic, valeric, and gluconic.
• suitable polymeric anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
• solvate is used herein in the conventional sense to refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
• chemically protected form pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions, that is, are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group).
• a protected or protecting group also known as a masked or masking group or a blocked or blocking group.
• the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
• an amine group may be protected, for example, as an amide or a urethane, for example, as: a methyl amide (-NHCO-CH 3 ); a benzyloxy amide (-NHCO-OCH 2 C 6 H 5 , -NH- Cbz); as a t-butoxy amide (-NHCO-OC(CH 3 ) 3 , -NH-Boc); a 2-biphenyl-2-propoxy amide (- NHCO-OC(CHS) 2 C 6 H 4 C 6 H 5 , -NH-Bpoc), as a 9-fluorenylmethoxy amide (-NH-Fmoc), as a 6- nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-NH-
• a carboxylic acid group may be protected as an ester for example, as: a Ci -7 alkyl ester (e.g. a methyl ester; a f-butyl ester); a Ci -7 haloalkyl ester (e.g. a Ci -7 trihaloalkyl ester); a triC 1-7 alkylsilyl-C 1-7 alkyl ester; or a C 5-20 aryl-C 1-7 alkyl ester (e.g. a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.
• a Ci -7 alkyl ester e.g. a methyl ester; a f-butyl ester
• a Ci -7 haloalkyl ester e.g. a Ci -7 trihaloalkyl ester
• prodrug refers to a compound which, when metabolised (e.g. in vivo), yields the desired active compound.
• the prodrug is inactive, or less active than the active compound, but may provide advantageous handling, administration, or metabolic properties.
• some prodrugs are esters of the active compound (e.g. a physiologically acceptable metabolically labile ester).
• Examples of such metabolically labile esters include, but are not limited to, those wherein R is C 1-2O alkyl (e.g. -Me, -Et); C 1-7 aminoalkyl (e.g.
• acyloxy-C 1-7 alkyl e.g. acyloxymethyl; acyloxyethyl; e.g.
• pivaloyloxymethyl acetoxymethyl; 1-acetoxyethyl; 1-(1- methoxy-1 -methyl)ethyl-carbonxyloxyethyl; 1 -(benzoyloxy)ethyl; isopropoxy- carbonyloxymethyl; 1-isopropoxy-carbonyloxyethyl; cyclohexyl-carbonyloxymethyl; 1 -cyclohexyl-carbonyloxyethyl; cyclohexyloxy-carbonyloxymethyl; 1 -cyclohexyloxy- carbonyloxyethyl; (4-tetrahydropyranyloxy) carbonyloxymethyl; 1-(4- tetrahydropyranyloxy)carbonyloxyethyl; (4-tetrahydropyranyl)carbonyloxymethyl; and 1-(4-tetrahydropyranyl)carbonyloxyethyl).
• prodrug forms include phosphonate and glycolate salts.
• hydroxy groups (-OH)
• Such a group can be cleaved by phosphatase enzymes during metabolism to yield the active drug with the hydroxy group.
• prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound.
• the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
• the A-B fused ring is shown as a fused benzene ring for convenience.
• Compounds in which the A-B ring is other than benzene may be synthesised using methodologies analogous to those described below by the use of appropriate alternative starting materials.
• n, R c1 , R C2 and X are as previously defined, in the presence of a coupling reagent system, for example 2-(1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate, 2- (1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate or (dimethylaminopropyl)ethylcarbodiimide hydrochloride/hydroxybenzotriazole, in the presence of a base, for example diisopropylethylamine, in a solvent, for example dimethylacetamide or dichloromethane, at a temperature in the range of 0 0 C to the boiling point of the solvent used.
• a coupling reagent system for example 2-(1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium t
• compounds of the present invention may be synthesised by conversion of a compound of Formula 1 into an activated species, for example an acid chloride or an activated ester such as an ⁇ /-hydroxysuccinimide ester, using well-known methodologies, and reaction of the activated species with a compound of Formula 2.
• an activated species for example an acid chloride or an activated ester such as an ⁇ /-hydroxysuccinimide ester
• R 1 is as previously defined, or a mixture of a compound of Formula 3 and a compound of Formula 4, with a source of hydrazine, for example hydrazine hydrate or hydrazine monohydrate, optionally in the presence of a base, for example triethylamine, optionally in the presence of a solvent, for example industrial methylated spirit, at a temperature in the range of 0 0 C to the boiling point of the solvent used.
• a source of hydrazine for example hydrazine hydrate or hydrazine monohydrate
• a base for example triethylamine
• a solvent for example industrial methylated spirit
• R 3 is a Ci -4 alkyl group
• a base for example triethylamine or lithium hexamethyldisilazide
• a solvent for example tetrahydrofuran
• a base for example triethylamine or lithium hexamethyldisilazide
• a solvent for example tetrahydrofuran
• Formula 10 by removal of the acetyl group using an acid, such as dilute sulphuric acid, in an organic solvent, for example, THF.
• an acid such as dilute sulphuric acid
• the compounds of Formula 10 can be synthesised from the respective compounds of Formulae 11a and 11b:
• the compounds of Formulae 11a and 11b can be synthesised from compounds of Formulae 12a and 12b respectively:
• oxidation for example by m-chloroperoxybenzoic acid (m-CPBA) in an organic solvent, such as DCM.
• m-CPBA m-chloroperoxybenzoic acid
• the compound of Formula 12a can be synthesised from a compound of Formula 13:
• Formula 13 by first reaction with iodomethane, followed by dropwise addtion of aqueous potassium cyanide to an ethanol-water solution of the product of the first step.
• the compound of Formula 12b can be synthesised from a compound of Formula 13 by first reaction with iodoethane, followed by dropwise addtion of aqueous potassium cyanide to an ethanol-water solution of the product of the first step.
• Formula 14 by oxidation of the alkene, for example, using ozone in a solution of the compound of Formula 14 in methanol and DCM (1:1) at -78°C.
• the compounds of Formula 15 can be synthesised from compounds of Formula 17:
• Formula 18 by hydrolysis of the cyano group, by, for example, sodium hydroxide in methanol.
• the compound of Formula 19 can be synthesised from a compound of Formula 20:
• the compound of Formula 21 can be synthesised from a compound of Formula 20:
• Formula 22 by deprotection of the aldehyde group using, for example, a mixture of acetone and water with a catalytic amount of pyridinium paratoluenesulfonate.
• the compound of Formula 22 can be synthesised from a compound of Formula 23:
• Formula 23 by reaction with a strong base, e.g. lithium diisopropyl amide (LDA), followed by addition of CO 2 .
• a strong base e.g. lithium diisopropyl amide (LDA)
• LDA lithium diisopropyl amide
• This reaction may, for example, be carried out at -78°C in THF, where the CO 2 is added as dry ice.
• the compound of Formula 23 can be synthesised from the compound of Formula 24:
• Formula 24 by protection of the aldehyde group, for example, by reaction with ethylene glycol (e.g. 1.5 equivalents) in the presence of a catalytic amount of paratoluenesulfonic acid in toluene, under relfux in a Dean-stark apparatus.
• ethylene glycol e.g. 1.5 equivalents
• the compound of Formula 24 can be synthesised from a compound of Formula 25: Formula 25 by reaction with a strong base, e.g. butyl lithium, followed by addition of DMF. This reaction may, for example, be carried out at -78°C.
• a strong base e.g. butyl lithium
• Compounds of Formula 1 may also be synthesised by methods analogous to those described above in which the nitrile moiety in all Formulae is replaced by other moieties capable of generating a carboxylic acid, for example ester or carboxamide moieties.
• R C1 , R C2 and R 1 are as previously defined. These compounds may be used to generate libraries of compounds of the invention as described below.
• R C3 is selected from the group consisting of optionally substituted Ci -2 o alkyl, C 5-2 O aryl and C 3-2O heterocyclyl, may be synthesised by reaction of a compound of Formula 26 with a compound of Formula R 03 COX, in which R C3 is as previously defined and X is a suitable leaving group, for example a halogen such as chloro, optionally in the presence of a base, for example pyridine, triethylamine or diisopropylethylamine, optionally in the presence of a solvent, for example dichloromethane, at a temperature in the range of 0°C to the boiling point of the solvent used.
• a base for example pyridine, triethylamine or diisopropylethylamine
• solvent for example dichloromethane
• Compounds of Formula 27 may also be synthesised by reaction of a compound of Formula 26 with a compound of Formula R 03 CO 2 H, in which R 03 is as previously defined, in the presence of a coupling reagent system, for example 2-(1 /-/-benzotriazol-1-yl)-1 , 1 ,3,3- tetramethyluronium tetrafluoroborate, 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate or (dimethylaminopropyl)ethylcarbodiimide hydrochloride/ hydroxybenzotriazole, in the presence of a base, for example diisopropylethylamine, in a solvent, for example dimethylacetamide or dichloromethane, at a temperature in the range of 0°C to the boiling point of the solvent used.
• a coupling reagent system for example 2-(1 /
• n, R c1 , R 02 and R 1 are as previously defined
• Y is O or S
• R N3 is selected from the group consisting of optionally substituted C 1-2 O alkyl, C 5-2 O aryl and C 3-2 O heterocyclyl, may be synthesised by reaction of a compound of Formula 26 with a compound of Formula R N3 NCY, in which Y and R N3 are as previously defined, in the presence of a solvent, for example dichloromethane, at a temperature in the range of 0 0 C to the boiling point of the solvent used.
• a solvent for example dichloromethane
• R C1 , R C2 and R 1 are as previously defined and R S1 is selected from the group consisting of optionally substituted C 1-20 alkyl, C 5-20 aryl and C 3-20 heterocyclyl, may be synthesised by reaction of a compound of Formula 26 with a compound of Formula R S1 SO 2 CI, in which R S1 is as previously defined, optionally in the presence of a base, for example pyridine, triethylamine or diisopropylethylamine, in the presence of a solvent, for example dichloromethane, at a temperature in the range of 0 0 C to the boiling point of the solvent used.
• a base for example pyridine, triethylamine or diisopropylethylamine
• R C4 and R C5 are each individually selected from the group consisting of H, optionally substituted C 1-20 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, or may together form an optionally substituted C 3 - 7 cycloalkyl or heterocyclyl group, may be synthesised by reaction of a compound of Formula 26 with a compound of Formula R C4 COR C5 , in which R C4 and R C5 are as previously defined, in the presence of a reducing agent, for example sodium cyanoborohydride or sodium triacetoxyborohydride, in the presence of a solvent, for example methanol, optionally in the presence of an acid catalyst, for example acetic acid, at a temperature in the range of 0 0 C to the boiling point of the solvent used.
• a reducing agent for example sodium cyanoborohydride or sodium triacetoxyborohydride
• solvent for example methanol
• an acid catalyst for example acetic acid
• the present invention provides active compounds, specifically, active in inhibiting the activity of PARP.
• active refers to compounds which are capable of inhibiting PARP activity, and specifically includes both compounds with intrinsic activity (drugs) as well as prodrugs of such compounds, which prodrugs may themselves exhibit little or no intrinsic activity.
• One assay which may conveniently be used in order to assess the PARP inhibition offered by a particular compound is described in the examples below.
• the present invention further provides a method of inhibiting the activity of PARP in a cell, comprising contacting said cell with an effective amount of an active compound, preferably in the form of a pharmaceutically acceptable composition. Such a method may be practised in vitro or in vivo.
• a sample of cells may be grown in vitro and an active compound brought into contact with said cells, and the effect of the compound on those cells observed.
• effect the amount of DNA repair effected in a certain time may be determined.
• the active compound is found to exert an influence on the cells, this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type.
• treatment pertains generally to treatment and therapy, whether of a human or an animal (e.g. in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition.
• Treatment as a prophylactic measure i.e. prophylaxis is also included.
• adjunct as used herein relates to the use of active compounds in conjunction with known therapeutic means.
• Such means include cytotoxic regimens of drugs and/or ionising radiation as used in the treatment of different cancer types.
• the active compounds are known to potentiate the actions of a number of cancer chemotherapy treatments, which include the topoisomerase class of poisons and most of the known alkylating agents used in treating cancer.
• Active compounds may also be used as cell culture additives to inhibit PARP, for example, in order to sensitize cells to known chemotherapeutic agents or ionising radiation treatments in vitro.
• Active compounds may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
• Administration may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
• the active compound or pharmaceutical composition comprising the active compound may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g.
• vaginal parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly.
• the subject may be a eukaryote, an animal, a vertebrate animal, a mammal, a rodent (e.g. a guinea pig, a hamster, a rat, a mouse), murine (e.g. a mouse), canine (e.g. a dog), feline (e.g. a cat), equine (e.g. a horse), a primate, simian (e.g. a monkey or ape), a monkey (e.g. marmoset, baboon), an ape (e.g. gorilla, chimpanzee, orangutang, gibbon), or a human.
• a rodent e.g. a guinea pig, a hamster, a rat, a mouse
• murine e.g. a mouse
• canine e.g. a dog
• feline e.g. a cat
• compositions comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
• the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilisers, or other materials, as described herein.
• pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• a subject e.g. human
• Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
• Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts. See, for example, "Handbook of Pharmaceutical Additives", 2nd Edition (eds. M. Ash and I.
• the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
• Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, losenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, electuaries, or aerosols.
• Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
• a tablet may be made by conventional means, e.g. compression or molding, optionally with one or more accessory ingredients.
• Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g. povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g. lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc, silica); disintegrants (e.g.
• Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
• the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyi cellulose in varying proportions to provide the desired release profile.
• Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
• Formulations suitable for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil.
• a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents.
• Formulations suitable for topical administration in the mouth include losenges comprising the active compound in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.
• Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.
• Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
• Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser include aqueous or oily solutions of the active compound.
• Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
• a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
• Formulations suitable for topical administration via the skin include ointments, creams, and emulsions.
• the active compound When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base.
• the active compounds may be formulated in a cream with an oil-in-water cream base.
• the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
• the topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
• the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
• an emulsifier otherwise known as an emulgent
• a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
• the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
• the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
• Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate.
• the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
• the cream should preferably be a non-greasy, non- staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
• Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
• Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
• Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.
• Formulations suitable for parenteral administration e.g., by injection, including cutaneous, subcutaneous, intramuscular, intravenous and intradermal
• parenteral administration include aqueous and non ⁇ aqueous isotonic, pyrogen-free, sterile injection solutions which may contain anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
• Suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer' s Solution, or Lactated Ringer' s Injection.
• concentration of the active compound in the solution is from about 1 ng/ml to about 10 ⁇ g/ml, for example from about 10 ng/ml to about 1 ⁇ g/ml.
• the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
• Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
• Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or more organs.
• appropriate dosages of the active compounds, and compositions comprising the active compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention.
• the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight, condition, general health, and prior medical history of the patient.
• the amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
• Administration in vivo can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
• a suitable dose of the active compound is in the range of about 100 ⁇ g to about 250 mg per kilogram body weight of the subject per day.
• the active compound is a salt, an ester, prodrug, or the like
• the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
• Samples were purified with a Waters mass-directed purification system utilising a Waters 600 LC pump, Waters Xterra C18 column (5 ⁇ m 19 mm x 50 mm) and Micromass ZQ mass spectrometer, operating in positive ion electrospray ionisation mode.
• Mobile phases A 0.1 % formic acid in water
• B 0.1 % formic acid in acetonitrile
• Analytical HPLC was typically carried out with a Spectra System P4000 pump and Jones Genesis C18 column (4 ⁇ m, 50 mm x 4.6 mm).
• Mobile phases A 0.1 % formic acid in water
• B acetonitrile
• Detection was by a TSP UV 6000LP detector at 254 nm UV and range 210-600 nm PDA.
• the Mass spectrometer was a Finnigan LCQ operating in positive ion electrospray mode.
• Dimethyl phosphite (22.0 g, 0.2 mol) was added drop-wise to a solution of sodium methoxide (43.0 g) in methanol (100 ml) at 0 0 C.
• 2-Carboxybenzaldehyde (21.0 g, 0.1 mol) was then added portion-wise to the reaction mixture as a slurry in methanol (40 ml), with the temperature kept below 5°C.
• the resulting pale yellow solution was warmed to 20 0 C over 1 hour.
• Methanesulphonic acid (21.2 g, 0.22 mol) was added to the reaction drop-wise and the resulting white suspension was evaporated in vacuo. The white residue was quenched with water, extracted with chloroform (3 x 100 ml).
• the phthalazinone core was formed on all compounds according to the protocol described above.
• DMSO DMSO being at a final concentration of 1 % per well.
• the total assay volume per well was 40 ⁇ l.
• IC 5O values (mean positive cpm - mean negative cpm) were calculated, which are determined over a range of different concentrations, normally from 10 ⁇ M down to 0.001 ⁇ M. Such IC 50 values are used as comparative values to identify increased compound potencies.
• the following compounds have an IC 50 of less than 0.1 ⁇ M: 1-7, 9-14, 17-18, 21 , 24, 26-29, 35, 50-52, 56-75.
• the Potentiation Factor (PF 50 ) for compounds is calculated as a ratio of the IC 50 Of control cell growth divided by the IC 50 Of cell growth + PARP inhibitor.
• Growth inhibition curves for both control and compound treated cells are in the presence of the alkylating agent methyl methanesulfonate (MMS).
• MMS alkylating agent methyl methanesulfonate
• SRB sulforhodamine B
• 2,000 HeLa cells were seeded into each well of a flat-bottomed 96- well microtiter plate in a volume of 100 ⁇ l and incubated for 6 hours at 37°C. Cells were either replaced with media alone or with media containing PARP inhibitor at a final concentration of 0.5, 1 or 5 ⁇ M.
• Cells were allowed to grow for a further 1 hour before the addition of MMS at a range of concentrations (typically 0, 1 , 2, 3, 5, 7 and 10 ⁇ g/ml) to either untreated cells or PARP inhibitor treated cells. Cells treated with PARP inhibitor alone were used to assess the growth inhibition by the PARP inhibitor.
• All the compounds tested had a PF 50 at 20OnM of at least 1.
• the following compounds had a PF 50 at 20OnM of at least 2: 2, 3, 5, 6, 9,10,12,13, 56, 57, 58, 62, 65, 66, 67, 74, 75.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Virology (AREA)
• Endocrinology (AREA)
• Oncology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Cardiology (AREA)
• Communicable Diseases (AREA)
• Emergency Medicine (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (4)

Publications (1)

Family

ID=35219560

Family Applications (1)

Country Status (11)

Cited By (37)

Families Citing this family (3)

Citations (6)

Family Cites Families (3)

• 2005
  • 2005-08-26 CA CA002577191A patent/CA2577191A1/en not_active Abandoned
  • 2005-08-26 EP EP05775527A patent/EP1791827A1/en not_active Withdrawn
  • 2005-08-26 AU AU2005276229A patent/AU2005276229A1/en not_active Abandoned
  • 2005-08-26 MX MX2007002318A patent/MX2007002318A/es active IP Right Grant
  • 2005-08-26 NZ NZ553979A patent/NZ553979A/en not_active IP Right Cessation
  • 2005-08-26 BR BRPI0514632-1A patent/BRPI0514632A/pt not_active IP Right Cessation
  • 2005-08-26 KR KR1020077006778A patent/KR20070057859A/ko not_active Application Discontinuation
  • 2005-08-26 JP JP2007528985A patent/JP2008510783A/ja active Pending
  • 2005-08-26 WO PCT/GB2005/003343 patent/WO2006021801A1/en active Application Filing
• 2007
  • 2007-02-18 IL IL181408A patent/IL181408A0/en unknown
  • 2007-03-26 NO NO20071579A patent/NO20071579L/no not_active Application Discontinuation

Patent Citations (6)

Also Published As

Similar Documents

Legal Events